Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Dongxuan LiChunmeng QinHongli WangDan DuYalan WangQian DuSongqing LiuPublished in: Therapeutic advances in drug safety (2024)
Our study showed the TLS risk characteristics of 164 antineoplastic agents by detecting and integrating ADR signals, which may help to optimize clinical practice.
Keyphrases